Hypercoagulability can result from a variety of inherited and, more commonly, acquired
conditions. Testing for the underlying cause of thrombosis in a patient is complicated both by …

Many patients have a variety of prothrombotic risk factors or conditions, and these patients
are often given anticoagulant/antithrombotic treatment. Such treatments for thromboembolic …

It is now possible to identify hereditary and acquired risk factors in a substantial percentage
of patients presenting with a venous thrombotic event. The clinician is faced with an ever …

This discussion considers several important hypercoagulable states that predispose patients
to venous, and in some instances, arterial thrombosis, focusing on activated protein C …

Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous
conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

The introduction of direct oral anticoagulant (DOAC) therapy into clinical use in the past 5
years has had significant impact on the clinical laboratory. Clinicians' desire to determine …

Sažetak The tests currently employed within most haemostasis laboratories to monitor
anticoagulant therapy largely comprise the prothrombin time (PT)/International Normalised …

Direct oral anticoagulants (DOACs) have demonstrated a favorable benefit–risk profile in
several thromboembolic disorders and are increasingly used in routine clinical practice. A …

Anticoagulant therapy, including conventional agents and a variety of new oral, fast-acting
drugs, is prescribed for millions of patients annually. Each anticoagulant varies in its effect …